M.A. Sanromán Guerrero, E. Hernández Sánchez, J.L. Zamorano Gómez
{"title":"肺动脉高压的治疗","authors":"M.A. Sanromán Guerrero, E. Hernández Sánchez, J.L. Zamorano Gómez","doi":"10.1016/j.med.2025.06.030","DOIUrl":null,"url":null,"abstract":"<div><div>In the past three decades, the treatment of choice for pulmonary hypertension has been based on three pharmacological groups targeting three distinct therapeutic targets along with a series of hygienic and dietary measures. Patients who do not respond to treatment are candidates for lung transplantation or palliative care if they are deemed ineligible for transplantation. Currently, a new drug class that acts on the activin pathway is showing highly promising results.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 37","pages":"Pages 2236-2245"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tratamiento de la hipertensión pulmonar\",\"authors\":\"M.A. Sanromán Guerrero, E. Hernández Sánchez, J.L. Zamorano Gómez\",\"doi\":\"10.1016/j.med.2025.06.030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>In the past three decades, the treatment of choice for pulmonary hypertension has been based on three pharmacological groups targeting three distinct therapeutic targets along with a series of hygienic and dietary measures. Patients who do not respond to treatment are candidates for lung transplantation or palliative care if they are deemed ineligible for transplantation. Currently, a new drug class that acts on the activin pathway is showing highly promising results.</div></div>\",\"PeriodicalId\":100912,\"journal\":{\"name\":\"Medicine - Programa de Formación Médica Continuada Acreditado\",\"volume\":\"14 37\",\"pages\":\"Pages 2236-2245\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine - Programa de Formación Médica Continuada Acreditado\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304541225001830\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine - Programa de Formación Médica Continuada Acreditado","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304541225001830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In the past three decades, the treatment of choice for pulmonary hypertension has been based on three pharmacological groups targeting three distinct therapeutic targets along with a series of hygienic and dietary measures. Patients who do not respond to treatment are candidates for lung transplantation or palliative care if they are deemed ineligible for transplantation. Currently, a new drug class that acts on the activin pathway is showing highly promising results.